Calidi Biotherapeutics develops targeted immunotherapies that attack solid tumors and aim to enhance the immune system's ability to combat cancer. The company is involved in clinical trials for its neural stem cells engineered to carry an oncolytic virus for treating recurrent high-grade glioma.

Calidi Biotherapeutics

Calidi Biotherapeutics | 2,536 followers on LinkedIn. Calidi Biotherapeutics is a clinical-stage biopharmaceutical company | Calidi Biotherapeutics is a clinical-stage biopharmaceutical company revolutionizing oncolytic viral therapies with stem cell-based platforms.

Quality Assurance Leader in Biotech/Pharma

Violet M. Carvalho

Chief Financial Officer

Andrew Jackson

Cofounder and Vice Chairman of Board of Directors Calidi Biotherapeutics

Scott Leftwich

Chief Business and Revenue Officer | Global

Steve Thesing

👏 Calidi Biotherapeutics recognizes Wendy Pizarro, Esq. , our Chief Legal Officer and Chief Diversity Officer, as a speaker today, October 21, 2024, at the San Diego Precision in Clinical Trials Summit in San Diego, CA. Sherri Monroe She will be speaking on Diversity, Equity and Inclusion Strategies in Clinical Trials and Patient Recruitment. Please reach out to her if you will be attending! #calidi #clinicaltrials #PCTSUMMIT #DEI #endcancer $CLDI

Calidi Biotherapeutics ' Chief Business Officer, Steve Thesing , recently interviewed with Dave Gentry , CEO of RedChip Companies , discussing Calidi's cancer therapies and their place in the future of oncology. Click below for the full interview: #calidi #oncology #virotherapy #endcancer $CLDI

Congratulations to Calidi Biotherapeutics ' Chief Legal Officer and Chief Diversity Officer, Wendy Pizarro, Esq. , for being awarded as a "2024 DEIA Visionary" by the L.A. Times B2B Publishing for her advocacy on health equity in innovative clinical trials. Read more here: https://lnkd.in/gd5v6aVf #DEI #healthequity #deia #indigenouspeoplesday

Calidi Biotherapeutics is thrilled to announce FDA Clearance of the Northwestern University IND Application for Calidi's NeuroNova (CLD-101) Clinical Trial in Newly Diagnosed High-Grade Glioma. Congratulations to the NWU and Calidi teams! Read more below: #calidi #IND #clinicaltrial #virotherapy #neuronova $CLDI #glioblastoma #highgradeglioma #braincancer

Missed Our Virtual Presentation? Watch the Replay Now! Yesterday, we at Calidi Biotherapeutics hosted an exciting virtual presentation diving deep into the groundbreaking science and innovative technology we’re developing to combat cancer. If you missed it, don’t worry! You can catch the full replay and discover how our pioneering approaches are transforming the future of cancer treatment. Watch the Replay Here: https://lnkd.in/gnGR7Fmf Join us on this journey towards a world free from the threat of cancer. Your support and curiosity drive our mission forward! #CalidiBio #CancerResearch #Biotechnology #Innovation #Science #Healthcare

Join Us for an Exciting Webinar: Calidi’s Groundbreaking Cancer Treatment 📅 Date: September 11th 🕓 Time: 4:15 PM ET Discover the future of cancer treatment with Calidi! Our developmental drug targets and destroys cancer cells throughout the body while leaving healthy cells unharmed. Don’t miss this opportunity to learn more about this revolutionary therapy. 🔗 Register now: #calidi #virotherapy #endcancer $CLDI

Calidi Biotherapeutics was recently featured in an article by Fred Grier with the San Diego Business Journal , highlighting the launch of our new subsidiary, Nova Cell. Read more below! #calidi #novacell #stemcells #biotech #sandiego $CLDI

📣 Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results. Read more below! #calidi #virotherapy #stemcells #biotech $CLDI

Calidi Biotherapeutics is proud to announce the launch of our new subsidiary, Nova Cell, and a $3 million aggregate investment from Dr. Ronald Rigor. Dr. Rigor, an accomplished Board-Certified Dermatologist, Internal Medicine, and Stem Cell Therapy expert has taken a significant step to advance regenerative medicine by investing in Nova Cell. “As the founder of one of the largest and fastest growing stem cell centers in the Philippines, I am delighted to partner with and invest in Nova Cell. This is a fantastic opportunity to provide best-in-class stem cell therapy treatments which could meet a huge unmet need in the Philippines. We look forward to bringing Nova Cell’s extensive experience in stem cell therapy production to provide innovative therapies to patients and to elevate the health and wellness industry in the Philippines.” - Dr. Rigor Read more below: #stemcell #calidi #NovaCell $CLDI

Calidi Biotherapeutics recently announced the issuance of a new U.S. patent covering our novel SuperNova technology! “This latest patent granted to Calidi covering meaningful features of our SuperNova platform represents an important milestone, as we prepare to advance CLD-201 into the clinic." - Allan Camaisa, CEO and Chairman. Read more below: #calidi #patent #SuperNova #virotherapy #stemcells $CLDI

Amazon

reCAPTCHA

IPv6

Cloudflare Hosting

Person Schema

Cloudflare

Gravatar Profiles

reCAPTCHA v2

HSTS IncludeSubdomains PreLoad

ASP.NET Ajax

CEO & Chair of the Board of Directors

Allan Camaisa

President, Medical & Scientific Affairs; Interim Chief Medical Officer

Boris Minev

Founder and Managing Director

Patrick Clark

Cofounder and Vice Chairman of Board of Directors

Chief Business Officer

Chief Legal Officer, Chief Administrative Officer, Chief Diversity Officer and Corporate Secretary

Wendy Pizarro. Esq.

SVP Technical Operations

Amish Patel

Chief Scientific Officer

Antonio Santidrian

Marketing Director (Consultant)

Aimee Eucce

Human Resources Director

Carol Hall

George Ng

Paul H. Neuharth, Jr.

Heehyoung Lee

James A. Schoeneck

Lisa Butterfield

Francesco Marincola

CEO and Chairman of the Board of Directors

President, Medical and Scientific Affairs; Interim Chief Medical Officer

Antonio Santidrian, PhD.

Vice President, R&D and Transitional Oncology

Duong Nguyen

Associate Director

Ivelina Minev

Sr. Manager of Clinical and Translational operations in R&D

Jared Hill

Corporate Counsel

Stephen Thesing

Chief Administrative Officer

Stephen Keane

IP and Business Development Officer

Western US Public Companies With Less Than $1B in Revenue

United States Public Companies With Fewer Than 50 Employees

Therapeutics Companies With Less Than $50M in Revenue (Top 10K)

Biotechnology Companies With More Than $1M in Revenue (Top 10K)

Calidi Biotherapeutics is a company that creates oncolytic virus-based immunotherapies to treat difficult-to-treat malignancies. The company focuses in immunotherapies developed using patented technology for the effective delivery of oncolytic viruses for targeted therapy, allowing healthcare practitioners to provide patients with innovative cancer treatments.

Post-IPO Equity - Calidi Biotherapeutics

Jackson Investment Group

Series B - Calidi Biotherapeutics

California Institute for Regenerative Medicine

Grant - Calidi Biotherapeutics

Convertible Note - Calidi Biotherapeutics

Series A - Calidi Biotherapeutics

Seed Round - Calidi Biotherapeutics

San Diego

California

United States

North America

Calidi Biotherapeutics Announces Proposed Public Offering

Preliminary option volume of 56.7M today

Calidi announces common stock offering, no amount given

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics’ $2.1 Million Shares Offering

Calidi Biotherapeutics warrants delist from NYSE (NYSE:CLDI)

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

Calidi Biotherapeutics files $25M mixed securities shelf (NYSE:CLDI)

Calidi Biotherapeutics, Inc. Announces Launch of Nova Cell Subsidiary

Composed of neural stem cells loaded with oncolytic adenovirus for treating glioblastoma, an aggressive brain or spinal cord cancer.

Uses adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus to treat advanced solid tumors.

A systemic enveloped oncolytic virotherapy designed to target all tumor sites.

A therapeutic candidate in the NeuroNova program using neural stem cells to deliver an oncolytic adenovirus to tumor sites, currently in Phase 1 clinical trials for recurrent high-grade glioma.

An upcoming cell-based oncolytic virotherapy for multiple solid tumors, expected to enter Phase 1 trials.

Kenya

Africa

Philippines

Asia

India

Indonesia

Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

news impact assignment basic	general
public peers	general	Nov 14, 2024 3:31 AM	958ae8d6
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 14, 2024 3:31 AM	65784380
crunchbase trigger	general	Nov 14, 2024 3:31 AM	a4260acb
crunchbase profile	general	Nov 15, 2024 12:12 AM	b9036fc0
li profile	general	Nov 14, 2024 3:31 AM	acfcd883
translate crunchbase fundingrounds	general	Nov 15, 2024 1:42 AM	ce89551c
peers	general	Nov 14, 2024 3:31 AM	8b2cfca7
news basic	general	Nov 14, 2024 3:31 AM	ec87ce1f
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:CALIDIBIO

Calidi Biotherapeutics

Last Close

2.29

21/11 21:00

Market Cap

28.12M

Beta: -

Volume Today

1.94M

Avg: -